Is Cellebrite (CLBT) Quietly Redefining Its Competitive Moat With Expanded Forensics and Cloud Testing?

• Cellebrite DI Ltd. recently released its Spring 2026 update, expanding lawful access across a wider range of iOS and Android devices, adding Safeguard Mode for time-sensitive data capture, introducing field-ready drone forensics, and bringing Corellium’s virtualized Arm-based testing environment into public preview on Google Cloud.
• By combining broader device coverage, cloud-based virtual testing and new drone data extraction, the release pushes Cellebrite further into complex, data-rich investigations and emerging automotive and industrial use cases.
• We’ll now examine how Corellium’s new Google Cloud availability and broader forensic capabilities may influence Cellebrite’s existing investment narrative.

Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

Cellebrite DI Investment Narrative Recap

To own Cellebrite, you need to believe its digital intelligence platform can stay essential as data volumes, device types and security protections keep increasing, while the business gradually reduces its reliance on lumpy U.S. federal spending. The Spring 2026 release helps near term by reinforcing Cellebrite’s ability to keep up with iOS and Android security, but it does not fundamentally change the key risk around government budget timing and visibility.

Among the recent announcements, Corellium’s public preview on Google Cloud looks most relevant here. It extends Cellebrite’s reach into Arm-based systems and automotive and industrial testing, directly tying into the catalyst that Corellium could expand the company’s total addressable market beyond government and law enforcement and, over time, modestly diversify revenue away from its most concentrated public sector exposures.

Yet against this product momentum, investors should be aware that increasing global privacy scrutiny could still...

Read the full narrative on Cellebrite DI (it's free!)

Cellebrite DI's narrative projects $771.9 million revenue and $132.7 million earnings by 2029. This requires 17.5% yearly revenue growth and a $54.9 million earnings increase from $77.8 million today.

Uncover how Cellebrite DI's forecasts yield a $21.67 fair value, a 96% upside to its current price.

Exploring Other Perspectives

While consensus focuses on steady growth, the most optimistic analysts once assumed revenue near US$735,000,000 and earnings above US$200,000,000 by 2028, viewing Corellium and Arm-based expansion as a powerful answer to rising privacy and regulatory risk, but you should weigh how this new release might shift both that bullish view and the concerns about stricter limits on digital evidence access.

Explore 7 other fair value estimates on Cellebrite DI - why the stock might be worth just $16.40!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cellebrite DI research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Cellebrite DI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cellebrite DI's overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
• Find 58 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com